Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...
Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...
DUBLIN - June 24, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 ...
The FDA has approved the MiniMed 670G system developed by Medtronic. It's a computer algorithm working with a continuous glucose monitor to learn an individual’s insulin needs. Then, it adjusts their ...
Leading medical device major Medtronic plcMDT recently announced that the U.S. FDA approval for its MiniMed 670G system, a Hybrid Closed Loop insulin delivery system. This system is the first of its ...
DUBLIN - May 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for the MiniMed(TM) 670G system, which is being used by more ...
The MiniMed 670G system measures glucose levels every 5 minutes and automatically adjusts insulin delivery to avoid highs and lows. The MiniMed 670G hybrid closed looped system (Medtronic), which ...
When Medtronic won approval for the MiniMed 670G from the FDA in 2016, it was a big deal. Advertised as “The World’s First Hybrid Closed Loop System,” it is the first commercial product of its kind – ...
Medtronic plcMDT recently announced FDA approval for its MiniMed 670G system for patients with type 1 diabetes between seven and 13 years of age. Notably, the approval was based on positive data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback